Your Messages Inbox (0) 
Your Unread Messages
See AllMost Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Top Ten Searches
post partum incontinence fibroid hpv colpotomy ovarian cyst curettage endometriosis intrauterine umbilical cordYour Article Summary
Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding
Inflammatory Bowel Disease, 11/04/09
Gisbert JP et al. – Certolizumab differs from infliximab and adalimumab in that it is a Fab fragment of an antitumor necrosis factor alpha monoclonal antibody, and therefore it may not be necessary to stop certolizumab in the third trimester. The use of infliximab is probably compatible with breast–feeding.
Related Articles
Novel Diagnostic and Prognostic Modalities in Inflammatory Bowel Disease
Gastroenterology Clinics of North America, 11/17/09
Relevance Score: 83%
Pregnancy and Inflammatory Bowel Disease
Gastroenterology Clinics of North America, 11/17/09
Relevance Score: 83%
Pathogenesis of inflammatory bowel disease (IBD)
The Internet Journal of Gastroenterology, 11/13/09
Relevance Score: 83%
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
The Lancet, 11/09/09
Relevance Score: 83%
Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history
Expert Review of Gastroenterology & Hepatology, 10/13/09
Relevance Score: 83%
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Urogenital Atrophy in Breast Cancer Survivors
Oncology Nursing Forum, 11/23/09
KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy
Annals of Surgical Oncology, 11/23/09
Importance of the development time of isolated bone metastasis in breast cancer
Langenbeck's Archives of Surgery, 11/23/09
Today in Maternal Fetal Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
Intrauterine growth restriction: new standards for assessing adverse outcome
Best Practice & Research Clinical Obstetrics & Gynaecology, 11/24/09
Anorectal symptoms during pregnancy: how important is trimester
International Journal of Colorectal Disease, 11/24/09
First-trimester use of paroxetine and congenital heart defects: A population-based case-control study
Birth Defects Research, 11/24/09
Sponsor
Article Search
Sponsor